Accendra Health, Inc. (ACH) Stock

Understand Accendra Health, Inc.: how it makes money

Accendra Health sells medical and surgical supplies to hospitals and healthcare providers, and earns service fees by managing their inventory and supply chain. Revenue splits between product markups and recurring service fees, with a growing patient-direct sleep channel; the company is still unprofitable at the operating level.

The profit engine is the markup on reselling medical supplies to hospitals (43% gross margin) plus recurring fees for managing their inventory, but declining volumes in core categories and payer payment delays keep the spread below the cost base.

Business quality (Weak): Weak. Revenue is shrinking 10% year over year, operating margin is negative, and ROE sits at -44%. The business has not yet proven it can convert its product-plus-service model into sustainable operating profit.

Bull case

• Sleep channel finally growing: The sleep category posted 5.5% growth in Q2 FY26, with equipment improving and supplies remaining strong, suggesting the patient-direct model is gaining real traction.
• Path to $100M free cash flow: Management targets approximately $100 million in normalized annual free cash flow, which would fund debt reduction from the current operating losses without continued equity issuance.
• New payer deals unlock volume: Newly signed payer agreements are expected to increase patient volume, supporting revenue growth through late-2026 and into 2027.

Bear case

• Respiratory and wound still shrinking: Respiratory and wound categories continued declining year over year, eroding the traditional product base that funds the service offering and compounds the 10% top-line drop.
• ATM dilution offsets debt cuts: The planned ATM equity program will issue new shares to pay down debt, diluting existing shareholders while the company still posts a -6% operating margin on $600M quarterly revenue.
• Audits drain cash and focus: Payer audits are delaying payments and pulling management resources away from automation and collection improvements, slowing the exact cost-reduction work needed to hit the FCF target.

Accendra Health, Inc. earnings call transcripts

• ACH Q2 FY26 earnings call transcript (reported 2026-08-10) · analysis
• ACH Q1 FY26 earnings call transcript (reported 2026-05-11) · analysis

All ACH earnings calls

Related Companies (Wholesale; 8 comparable wholesalers)

• Envista Holdings Corp (NVST)
• Insulet Corporation (PODD)
• Revvity, Inc. (RVTY)
• Globus Medical, Inc. (GMED)
• Henry Schein, Inc. (HSIC)
• Bio-Rad Laboratories, Inc. (BIO)
• West Pharmaceutical Services, Inc. (WST)
• MiniMed Group, Inc. (MMED)